Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03124498 | A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA | unknown | Phase 1 / Phase 2 | 55 | Chuan An Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 21, 2017 |
| clinicaltrials |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | terminated | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT03084380 | Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT01656265 | Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 24 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01668134 | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 28 | Washington University School of MedicineOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00516165 | RAD001 in Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 / Phase 2 | 0 | Philipps University MarburgOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT02959151 | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | unknown | Phase 1 / Phase 2 | 20 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT01308723 | A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01897038 | A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT00846131 | Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma | completed | Phase 1 | 24 | Northwestern UniversityOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02882659 | Dendritic Killer Cell-based Immunotherapy for Solid Tumors | unknown | Phase 1 | 18 | FullHope Biomedical Co., Ltd.INDUSTRY | 0 | Aug 30, 2016 | clinicaltrials |
| NCT01733004 | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Merrimack PharmaceuticalsINDUSTRY | 2 | Aug 4, 2016 | clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT02399735 | Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation | unknown | Phase 1 | 18 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT02772029 | A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT01008566 | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | May 12, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | unknown | Phase 1 | 112 | e-Therapeutics PLCINDUSTRY | 4 | Apr 6, 2016 | clinicaltrials |
| NCT02727309 | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | unknown | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02586285 | Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma | unknown | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02587884 | Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH | unknown | Phase 1 | 180 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724332 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | completed | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT02210182 | A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma | completed | Phase 1 | 29 | Oncozyme Pharma Inc.INDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01147380 | Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation(MIAMINK) | completed | Phase 1 | 18 | Seigo NishidaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02101593 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT01594125 | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT02403544 | Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma | unknown | Phase 1 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT02632006 | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02638857 | Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT00669136 | Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma | terminated | Phase 1 | 2 | Lisa H. Butterfield, Ph.D.OTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01521780 | Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) | terminated | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 2, 2015 | clinicaltrials |
| NCT02578602 | MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer | completed | Phase 1 | 26 | University of Southern CaliforniaOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT01348503 | Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma | terminated | Phase 1 | 5 | Indiana UniversityOTHER | 1 | Aug 31, 2015 | clinicaltrials |
| NCT02528526 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm(OXY1A) | unknown | Phase 1 / Phase 2 | 69 | University of ZurichOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00997022 | Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | completed | Phase 1 | 14 | Columbia UniversityOTHER | 1 | Aug 10, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01406574 | Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 23 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | completed | Phase 1 / Phase 2 | 81 | Southwestern Regional Medical CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Apr 25, 2017source: clinicaltrials